0QPY Stock Chart & Stats
CHF218.00
CHF7.33(3.48%)
At close: 4:00 PM EDT
CHF218.00
CHF7.33(3.48%)
Day’s Range― - ―
52-Week RangeCHF163.20 - CHF245.80
Previous CloseN/A
Volume51.96K
Average Volume (3M)79.97K
Market Cap
CHF12.66B
Enterprise ValueCHF12.74B
Total Cash (Recent Filing)CHF722.10M
Total Debt (Recent Filing)CHF1.71B
Price to Earnings (P/E)30.4
Beta1.17
Next Earnings
Nov 12, 2026EPS Estimate
4.37Next Dividend Ex-DateN/A
Dividend Yield2.12%
Share Statistics
EPS (TTM)7.23
Shares Outstanding59,626,810
10 Day Avg. Volume57,051
30 Day Avg. Volume79,969
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.15
Price to Sales (P/S)3.00
P/FCF Ratio17.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF197.67Price Target Upside-9.33% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)10.64
Revenue Forecast (FY)CHF3.82B
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSonova's structurally high gross margins and historically healthy net margins reflect strong product pricing, proprietary technology and recurring accessory/after‑sales streams. These margin advantages support reinvestment in R&D and retail expansion, helping sustain returns through cycles.
Strong Cash GenerationConsistent FCF conversion versus reported earnings gives Sonova durable internal funding for R&D, bolt‑on retail M&A and capex without heavy external reliance. That cash resilience underpins strategic flexibility and cushions execution risk from product cycles or temporary demand softness.
Product & Channel MomentumOngoing product innovation (AI-enabled platforms, rechargeable ITE) plus wholesale market‑share gains and retail expansion create durable competitive advantage. A broad pipeline and omni‑channel distribution increase upgrade pools and support sustainable revenue and share growth over the medium term.
Bears Say
Top-line SoftnessThe recent revenue decline and margin compression reduce operating leverage and can erode the cushion that funds R&D and store rollouts. If top‑line weakness persists it could force tighter investment or slower M&A, undermining medium‑term growth aspirations.
Cochlear Implants WeaknessCI underperformance, falling system and upgrade sales and heightened competition indicate structural challenges in that division. Recovery depends on a new processor and regulatory timing; any delays or approval setbacks could extend revenue and recurring upgrade shortfalls for multiple quarters.
Elevated LeverageWhile leverage is currently manageable, persistent elevated debt with limited equity growth constrains financial flexibility for larger strategic moves. This restricts the firm's ability to pursue transformational M&A or absorb prolonged weakness without increasing funding costs or diluting returns.
Sonova Holding AG News
0QPY FAQ
What was Sonova Holding AG’s price range in the past 12 months?
Sonova Holding AG lowest share price was CHF163.20 and its highest was CHF245.80 in the past 12 months.
What is Sonova Holding AG’s market cap?
Sonova Holding AG’s market cap is CHF12.66B.
When is Sonova Holding AG’s upcoming earnings report date?
Sonova Holding AG’s upcoming earnings report date is Nov 12, 2026 which is in 100 days.
How were Sonova Holding AG’s earnings last quarter?
Sonova Holding AG released its earnings results on May 18, 2026. The company reported CHF5.67 earnings per share for the quarter, missing the consensus estimate of CHF5.706 by -CHF0.036.
Is Sonova Holding AG overvalued?
According to Wall Street analysts Sonova Holding AG’s price is currently Overvalued.
Does Sonova Holding AG pay dividends?
Sonova Holding AG pays a Annually dividend of CHF4.7 which represents an annual dividend yield of 2.12%. See more information on Sonova Holding AG dividends here
What is Sonova Holding AG’s EPS estimate?
Sonova Holding AG’s EPS estimate is 4.37.
How many shares outstanding does Sonova Holding AG have?
Sonova Holding AG has 59,626,810 shares outstanding.
What happened to Sonova Holding AG’s price movement after its last earnings report?
Sonova Holding AG reported an EPS of CHF5.67 in its last earnings report, missing expectations of CHF5.706. Following the earnings report the stock price went up 7.762%.
Which hedge fund is a major shareholder of Sonova Holding AG?
Currently, no hedge funds are holding shares in GB:0QPY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonova Holding AG
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.
0QPY Stock 12 Month Forecast
Average Price Target
CHF197.67
▼(-9.33% Downside)
Technical Analysis
Straumann Holding AG
―
Medacta Group SA
―
Tecan Group AG
―
Ypsomed Holding AG
―
Medartis Holding AG
―





